|Dr. David R. Guyer M.D.||Co-Founder & Exec. Chairman||960.71k||7.87M||57|
|Mr. Glenn P. Sblendorio M.B.A.||Pres, CEO & Director||746.11k||N/A||61|
|Dr. Samir C. Patel M.D.||Co-Founder and Consultant||947.79k||468.62k||56|
|Ms. Barbara A. Wood Esq.||Sr. VP, Gen. Counsel & Sec.||551.43k||51.88k||54|
|Mr. David F. Carroll M.B.A.||CFO & Treasurer||N/A||N/A||51|
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.
Ophthotech Corporation’s ISS Governance QualityScore as of December 1, 2017 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 10.